XML 15 R48.htm IDEA: XBRL DOCUMENT v3.2.0.727
Fair Value Measurement - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2015
EUR (€)
Jun. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
Jun. 02, 2014
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Fair value of other assets $ 0   $ 0        
Fair value of other liabilities 0   0        
Increase to milestone payment 768,556 $ 17,700 1,880,930   $ 116,020    
Payment of contingent considerations     99,000        
Accrued Balance             $ 1,370,000
Refine Technology, LLC              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Increase to milestone payment     1,864,000        
Refine Technology, LLC | Milestone Payments              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Payment of contingent considerations     1,000,000        
Accrued Balance             $ 1,370,000
Bio Flash | Minimum              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Royalty payment     110,000        
Novozymes Biopharma DK A/S Sweden Ab | Milestone Payments              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Payment of contingent considerations     27,700 € 25,000      
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Increase to milestone payment     1,864,000        
Accrued Balance $ 4,185,000   $ 4,185,000        
Scenario, Forecast | Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Accrued Balance           $ 4,185,000